124 Illegal Sales of 'Slimming Pens' Detected in Pharmacies and Clinics; Over NT$3.55 Million in Fines Imposed

The Taiwan Food and Drug Administration (TFDA) has reported 124 cases of illegal sales of GLP-1 receptor agonists, commonly known as "slimming pens," by pharmacies and medical institutions since 2024. Violations include operating without a pharmaceutical license and selling prescription-only drugs without valid prescriptions, resulting in a total of NT$3.555 million in fines.

Currently, three active ingredients—tirzepatide, semaglutide, and liraglutide—are approved for weight management in Taiwan. All are classified as prescription drugs that require professional medical assessment and proper dispensing by a pharmacist.

In response to the prevalence of illicit online and private channels, the TFDA has collaborated with local health bureaus since 2024 to strengthen inspections. Reported violations range from improper dispensing procedures and lack of required medical records to the sale of prescription drugs without prescriptions.

Additionally, the TFDA has partnered with professional pharmacy associations and network authorities to monitor digital platforms. As of June 11, 2026, over 1,197 illegal posts on platforms such as Facebook and Threads have been removed, and 5 illicit sales websites have been blocked.

The TFDA emphasizes that while some weight-loss injections are approved for adolescents aged 12 and older under medical supervision, most are restricted to adults meeting specific BMI criteria. Consumers are urged to consult licensed medical professionals through legal channels to ensure safety.